Lung Cancer (NSCLC)

Oncology
3
Pipeline Programs
5
Companies
4
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
1 program
1
CemiplimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT07450183Not Yet Recruiting33Est. Dec 2027
Pfizer
PfizerNEW YORK, NY
1 program
1
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant SugemalimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06987734RecruitingEst. Aug 2028
Phrontline Biopharma
Phrontline BiopharmaChina - Shanghai
1 program
1
TJ101Phase 11 trial
Active Trials
NCT07181473RecruitingEst. Sep 2027
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Cryobiopsy of lymph nodes group 6 secN/A1 trial
Active Trials
NCT06921681RecruitingEst. Dec 2029

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
RegeneronCemiplimab
PfizerNeoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab
Phrontline BiopharmaTJ101
City TherapeuticsCryobiopsy of lymph nodes group 6 sec

Clinical Trials (4)

Total enrollment: 33 patients across 4 trials

NCT07450183RegeneronCemiplimab

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

Start: Jun 2026Est. completion: Dec 202733 patients
Phase 2Not Yet Recruiting
NCT06987734PfizerNeoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab

Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients

Start: Jun 2025Est. completion: Aug 2028
Phase 2Recruiting
NCT07181473Phrontline BiopharmaTJ101

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

Start: Aug 2025Est. completion: Sep 2027
Phase 1Recruiting
NCT06921681City TherapeuticsCryobiopsy of lymph nodes group 6 sec

Ultrasound-guided Cryobiopsy of Mediastinal/Hilar Lymph Nodes

Start: Mar 2025Est. completion: Dec 2029
N/ARecruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 33 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)